PROTHENA CORP PLC (PRTA)
IE00B91XRN20 - Common Stock
Noteworthy Wednesday Option Activity: PRTA, CNK, ETSY
Prothena Enters Oversold Territory (PRTA)
Prothena Enters Oversold Territory (PRTA)
Prothena Announces Leadership Team Updates
Prothena to Participate in Upcoming Healthcare Conferences
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024
PRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prothena Corp (NASDAQ:PRTA) just reported results for the second quarter of 202...
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
Commit To Purchase Prothena At $17.50, Earn 34.3% Annualized Using Options
Prothena to Report Second Quarter 2024 Financial Results on August 8
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024
PRTA stock results show that Prothena Corp missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Prothena Corp (NASDAQ:PRTA) just reported results for the first quarter of 2024...
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
Prothena to Report First Quarter 2024 Financial Results on May 8
Commit To Buy Prothena Corp At $15, Earn 21.3% Using Options
Commit To Purchase Prothena Corp At $15, Earn 21.3% Using Options
Prothena is Now Oversold (PRTA)
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Prothena to Participate in Upcoming Healthcare Conferences
Prothena Appoints David Ford to Newly Created Chief People Officer Position
Prothena files to offer ordinary shares (NASDAQ:PRTA)
Prothena files prospectus for offering of ordinary shares without disclosing the amount. This is not an offer to sell securities.
Prothena appoints Daniel G. Welch as Chair Designate (NASDAQ:PRTA)
Prothena Corporation appoints Daniel G. Welch as an independent director and Chair Designate, with plans to elect him as Chair of the Board later this year.
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
Prothena GAAP EPS of -$1.26 misses by $0.03, revenue of $0.32M misses by $2.4M (NASDAQ:PRTA)
Prothena's Q4 financial results fall short as EPS and revenue miss expectations.
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
